Drugs in MeSH Category Antinematodal Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax Labs Inc	EMVERM	mebendazole	TABLET, CHEWABLE;ORAL	073580-001	Jan 4, 1995		RX	No	Yes
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	017481-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Bayer Pharms	NICLOCIDE	niclosamide	TABLET, CHEWABLE;ORAL	018669-001	May 14, 1982		DISCN	No	No
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	208398-001	Oct 19, 2016		DISCN	Yes	No
Janssen Pharma	ERGAMISOL	levamisole hydrochloride	TABLET;ORAL	020035-001	Jun 18, 1990		DISCN	No	No

Last updated: July 20, 2026

Market Dynamics and Patent Landscape for Antinematodal Agents (NLM MeSH): Which Drugs Have the Biggest IP and Exclusivity Exposure?

The MeSH category Antinematodal Agents covers a broad set of systemic anti-parasitic medicines and a smaller set of niche agents. From an IP and market-dynamics standpoint, the category is dominated by (1) widely used generics with limited enforceable exclusivity in core geographies, and (2) patent-protected newer entrants where lifecycle management and method-of-use or formulation claims can still delay generic entry. Key market drivers are WHO-linked mass drug administration demand, payer and procurement procurement cycles, and the speed at which FDA/EMA approvals translate into price competition once patent barriers clear.

This analysis maps the patent landscape by active ingredient and drug class patterns typical for nematicides in humans: benzimidazoles (Albendazole, Mebendazole), macrocyclic lactones (Ivermectin), nicotinic acetylcholine receptor agonists (Levamisole), and newer/less common pipeline or repositioned products depending on jurisdiction.

Because “Antinematodal Agents” is a MeSH umbrella rather than a single drug, the actionable lens is: identify which specific products in that MeSH bucket still sit on enforceable IP and exclusivity in the US/EU/major markets, then connect those barriers to generic or follow-on product risks and procurement realities.

---

Which antinematodal agents dominate MeSH “Antinematodal Agents” market demand and payer procurement?

Featured snippet answer: Demand is concentrated in a handful of actives used in mass drug administration and routine parasitic disease management, with albendazole, ivermectin, and mebendazole typically carrying the highest volume exposure; IP risk at category level depends on whether a country is still reliant on origin brands versus generic tender supply.

Core market dynamics by therapeutic use pattern

Mass drug administration (MDA) cycle

• Contract awards often span multiple years; price resets follow patent expiry and entry of low-cost generics.
• WHO and national programs tend to shift supply rapidly once multiple qualified suppliers exist.

Guideline-led routine use

• Point-of-care or clinic use (strongyloidiasis, pinworm, ascariasis) can keep origin brands viable until the first wave of generics fully penetrates.

Geography matters more than molecule class

• US and EU: patent and regulatory exclusivity drive timing for generics.
• High-burden markets: tender-based generic substitution can reduce brand economics even before formal patent expiry, if licensing or compulsory procurement arrangements exist.

Competitive structure typical for the category

Segment	Typical products	Competitive outcome	IP relevance
Bulk MDA benzimidazoles	Albendazole, mebendazole	Rapid generic-led price compression	Older patents often expired; formulation and polymorph claims matter less unless still enforced
Core systemic ivermectin demand	Ivermectin	Tender supply plus brand remnants in some markets	Origin patents generally older; lifecycle claims may still matter in specific jurisdictions
Less common or regional agents	Levamisole and others	Smaller footprint, more local competition	Method-of-use and solid-state form coverage can still be used to block “work-alike” approaches

---

What patents protect albendazole and mebendazole in the US and major export markets?

Featured snippet answer: For benzimidazoles, most enforceable patent coverage is usually limited to specific solid-state forms, manufacturing methods, or combination products; core “drug substance” patents typically predate current MDA demand cycles, so generic entry risk often depends on formulation and process patents rather than the API itself.

Patent estate structure for benzimidazoles (how IP usually persists)

1. Polymorphs / solid-state forms
   • Coverage can extend beyond earliest compound filing via new crystalline forms or stabilized amorphous variants.
2. Formulation patents
   • Tablets, suspensions, granules, chewables. For pediatric use, formulation-specific claims can be meaningful.
3. Manufacturing and particle engineering
   • Milling, micronization, wet granulation, and controlled release manufacturing steps.
4. Method-of-use claims
   • Less common for the long-established actives, but can exist where dosing regimen innovation is pursued.

Market impact of these IP patterns

• If the origin company holds only late-life formulation/process claims, the economic barrier to generics is lower than a new “use” or “combination” patent estate.
• Procurement programs often accept bioequivalent generics; so the practical barrier is whether an approved generic can legally manufacture a covered form/process in a key market.

---

When does ivermectin lose exclusivity for nematode indications, and what generic entry risks remain?

Featured snippet answer: In ivermectin’s case, generic entry risk is often less about “drug exclusivity” and more about whether any late-life formulation, method-of-use, or pediatric dosing innovations still have enforceable claims in the target jurisdiction.

Exclusivity framework that typically drives timing

• Regulatory exclusivity (where applicable) is generally shorter than patent life, and many anti-parasitic approvals predate current regulatory exclusivity regimes.
• Orange Book-type listings (US) control the timing of Paragraph IV challenges for FDA-approved, patent-listed products.
• If only formulation or process patents remain, the first generics can still appear but may need “design-around” choices to avoid infringement.

Practical generic entry risks for ivermectin

Risk driver	How it blocks generics	Typical workaround
Solid-state or formulation patent	Generic must avoid matching a protected form or composition	Different excipient matrix or different form not covered
Process/milling/manufacturing claims	Generic may be blocked even with equivalent final API	Alternate manufacturing route that does not practice the claim
Method-of-use dosing claims	Generic with same dosage schedule risks infringement	Different dosing regimen not within the claimed method

---

What formulation patents exist for antinematodal agents and how do they affect generic bioequivalence strategies?

Featured snippet answer: Formulation patents can be the most durable IP layer in nematode drugs because generics may achieve bioequivalence at the API level but still infringe excipient systems, particle size specifications, or release profiles if the claims are drafted to those product attributes.

Formulation IP hotspots by product type

1. Oral suspension and pediatric formulations
   • Particle size distributions, viscosity targets, and stability criteria.
2. Chewable tablets
   • Flavoring/excipient systems can be claimable when linked to stability or release characteristics.
3. Micronized or controlled-release variants
   • Particle engineering can be claimed even when the API stays the same.

Generic strategy implications

• Generics can pursue:
  • Different excipient system,
  • Different particle size target,
  • Different granulation route,
  • Different release mechanism.
• Legal risk remains highest where patents claim product-by-process attributes or tight ranges that are hard to decouple from manufacturing reality.

---

Which antinematodal drugs have method-of-use patent coverage for specific nematode species or dosing regimens?

Featured snippet answer: Method-of-use coverage, when present in antinematodal agents, typically ties dosing schedule, patient subgroup (pediatric, immunocompromised), or specific organism context (for example, strongyloidiasis vs other helminths). Where such claims exist, they can delay “label matching” generics even when API patents are expired.

Typical claim language patterns (what to look for)

• “A method of treating [condition] in a subject comprising administering…”
• Dosage amount and frequency ranges.
• Treatment duration.
• Concomitant regimen, such as combination dosing windows.

Market impact

• If US or EU labeling is used for method-of-use infringement mapping, the practical barrier becomes:
  • Whether generics seek “label carveouts” or narrow their indicated population,
  • Whether payers can tolerate non-identical labeling.

---

How many patents cover each major antinematodal drug, and which assignees hold the largest estates?

Featured snippet answer: The number of patents per active ingredient tends to be low for benzimidazoles at the “core compound” level but higher when lifecycle patents for formulations and manufacturing are counted. The biggest estates are typically held by originators that maintained presence through generics and formulation upgrades rather than pure compound developers.

Estate scoring model for decision-making

Estate layer	What it includes	Why it matters
Core substance patents	Compound composition and early salts/polymorphs	Often expired or near-expiry
Formulation patents	Tablet/suspension/chewable compositions, release specs	Can block generic “same product” replication
Process patents	Manufacturability constraints	Can drive litigation even with different formulation
Method-of-use patents	Label-adjacent regimens	Can delay label-aligned generics

Assignee pattern typical for the class

• Originator lifecycle holders tend to be large branded antiparasitic companies.
• For generic-heavy molecules, assignee count increases via continuations and formulation patent licensing to local manufacturers.

---

What Paragraph IV patent challenges have affected antinematodal agents, and which settlements matter?

Featured snippet answer: Paragraph IV activity for long-established antinematodal agents is usually sporadic because core compound patents often lapsed years earlier; when challenges occur, they most often target formulation or process patents listed in the Orange Book for a particular branded product.

How to interpret litigation for this MeSH bucket

• “Win” for a generic often requires:
  • Narrow invalidation of formulation/process claims,
  • Successful design-around,
  • Or a settlement that allows launch at a defined date.
• “Win” for originators typically depends on claim construction on:
  • Composition ranges,
  • Particle size,
  • Product-by-process parameters.

---

What is the Orange Book status of major antinematodal brands, and what does it imply for launch timing?

Featured snippet answer: For major oral antinematodal actives, Orange Book coverage commonly persists primarily for branded formulations or specific dosing presentations; the number of listed patents is the best proxy for launch friction in the US, while expiration dates plus generic ANDA approvals determine realistic entry.

How to use Orange Book listings for this category

• Identify:
  • Patent list count for each NDA,
  • Earliest expiration date across drug substance, formulation, method-of-use,
  • Any listed exclusivity blocks.
• Then map:
  • Which patents are likely infringed by a bioequivalent generic,
  • Which patents are “design-around” approachable.

---

Do biosimilars matter for antinematodal agents, or is this space purely small-molecule?

Featured snippet answer: Antinematodal Agents is overwhelmingly small-molecule and oral/injectable drug products; biosimilars are not a primary risk driver for this MeSH category.

Practical implication

• Generic competition is the main regulatory/IP disruptor, not biosimilar entry.
• Regulatory risk focuses on ANDA-type pathways and Paragraph IV challenges in the US or equivalent generic approval rules elsewhere.

---

How does the patent landscape differ between US, EU, and key procurement markets for antinematodal drugs?

Featured snippet answer: US litigation and Orange Book listings create sharper, faster patent enforcement leverage; EU coverage depends more on EPO-granted patents and national enforcement, while procurement-heavy markets may see generics commercialize faster via tender substitution, regardless of remaining method/formulation claims.

Jurisdictional enforcement pattern

Jurisdiction	Typical enforcement mechanics	Practical impact on market
US	Orange Book listings, ANDA/Paragraph IV litigation	Deterministic launch delay if patents are upheld
EU	National infringement actions for EP patents	Timing can be slower, but injunction leverage matters
High-burden markets	Patent enforcement varies widely	Generic penetration can outpace brand economics

---

Which antinematodal active ingredients have the strongest remaining IP posture for investors or licensors?

Featured snippet answer: IP strength tends to concentrate in products where lifecycle patents still cover:

• a differentiated pediatric or solid-state formulation,
• a specific dosing regimen,
• or a combination product with sustained label utility.

Investor-facing diligence checklist (for this MeSH category)

• Patent claim type concentration:
  • Formulation and process claims can be enforceable but may be easier to design around.
  • Method-of-use claims align tightly with label and can be harder to evade.
• Expiration clustering:
  • If expirations cluster within 12 to 24 months in key markets, deal value drops sharply.
• Litigation status:
  • If any patents are already construed against the originator, commercial exclusivity is likely reduced.

---

Key Takeaways

• The MeSH “Antinematodal Agents” market is dominated by long-established oral actives where generic competition is structural and patent estates tend to persist through formulation and process patents rather than core drug substance.
• Patent-driven delay in the US typically depends on Orange Book-listed formulation/process/method-of-use patents tied to specific branded presentations.
• Biosimilar risk is not a material driver in this category; ANDA-style generic pathways and design-around strategies are the primary disruptors.
• For licensing and investment decisions, the strongest residual IP posture usually comes from differentiated pediatric or solid-state formulations and label-adjacent method-of-use claims with enforceable jurisdiction-specific coverage.

---

FAQs

1. Which antinematodal drugs have the highest number of Orange Book-listed patents per NDA?
2. What claim types in antinematodal formulations are most vulnerable to generic design-around (excipients vs particle size)?
3. How do settlement agreements typically schedule generic launch dates for anti-parasitic formulation patents?
4. What is the most common strategy origins use to extend antinematodal exclusivity after core compound expiry?
5. Which jurisdictions outside the US most often allow commercial generic substitution despite remaining formulation or method-of-use patents?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. National Library of Medicine. (n.d.). MeSH: Antinematodal Agents. https://meshb.nlm.nih.gov/
4. European Medicines Agency. (n.d.). EMA medicines. https://www.ema.europa.eu/en/medicines